PE20011316A1 - Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada - Google Patents

Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada

Info

Publication number
PE20011316A1
PE20011316A1 PE2001000306A PE2001000306A PE20011316A1 PE 20011316 A1 PE20011316 A1 PE 20011316A1 PE 2001000306 A PE2001000306 A PE 2001000306A PE 2001000306 A PE2001000306 A PE 2001000306A PE 20011316 A1 PE20011316 A1 PE 20011316A1
Authority
PE
Peru
Prior art keywords
oxo
phenylpropyl
mercapto
amino
acid
Prior art date
Application number
PE2001000306A
Other languages
English (en)
Inventor
Robert A Wolf
Richard A Reeves
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20011316A1 publication Critical patent/PE20011316A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN INHIBIDOR DE LA VASOPEPTIDASA TAL COMO ACIDO [4S-[4O(R*),7O,10aß]]-OCTAHIDRO-4-[(2-MERCAPTO-1-OXO-3-FENILPROPIL)AMINO]-5-OXO-7H-PIRIDO[2,1-b][1,3]TIAZEPIN-7-CARBOXILICO DE FORMULA I (OMAPATRILAT) , EL ACIDO [S-(R*,R*)]-HEXAHIDRO-6-[(2-MERCAPTO-1-OXO-3-FENILPROPIL)AMINO-2,2-DIMETIL-7-OXO-1H-AZEPIN-1-ACETICO DE FORMULA II (GEMOPATRILAT) Y b) UN AGENTE HIPERTENSOR ENTRE ELLOS i) DIURETICOS COMO HIDROCLOROTIAZIDA, ii) AGENTES O-BLOQUEADORES Y/O ß-ADRENERGICOS COMO PROPANOLOL, MALEATO DE TIMOLOL, CARVEDILOL, ATENOLOL, iii) BLOQUEADORES DE LA ENTRADA DE CALCIO COMO AMLODIPINA, CLORHIDRATO DE DIALTIAZEM, CLORHIDRATO DE VERAPAMIL, iv) ANTAGONISTAS DEL RECEPTOR DE LA ANGIOTENSINA II COMO LOSARTAN, IRBESARTAN, VALSARTAN, EPROSARTAN, v) INHIBIDOR DE LA HMG-CoA-REDUCTASA COMO SIMVASTATINA, LOVASTATINA, ATORVASTATINA, ENTRE OTROS, vi) INHIBIDOR DE LA AGREGACION PLAQUETARIA COMO BISULFATO DE CLOPIDOGREL, CLORHIDRATO DE TICLOPIDINA, ASPIRINA. LA COMPOSICION ES UTIL PARA REDUCIR LA FRECUENCIA DE LA ENFERMEDAD CORONARIA Y EL TRATAMIENTO DE LA HIPERTENSION SISTOLICA AISLADA
PE2001000306A 2000-04-03 2001-04-03 Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada PE20011316A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19449900P 2000-04-03 2000-04-03

Publications (1)

Publication Number Publication Date
PE20011316A1 true PE20011316A1 (es) 2002-01-13

Family

ID=22717832

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000306A PE20011316A1 (es) 2000-04-03 2001-04-03 Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada

Country Status (8)

Country Link
US (1) US20020004500A1 (es)
EP (1) EP1267855A2 (es)
JP (1) JP2003533440A (es)
AU (1) AU2001287289A1 (es)
CA (1) CA2405496A1 (es)
PE (1) PE20011316A1 (es)
UY (1) UY26648A1 (es)
WO (1) WO2001074348A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251500T3 (es) * 2000-07-13 2006-05-01 Alteon, Inc. Tiazolios e imidazolios sustituidos por cianometilo y tratamientos de desordenes asociados al envejecimiento proteinico.
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20030144269A1 (en) * 2001-12-20 2003-07-31 Block Alan J. Reducing pulse pressures and vascular stiffness in hypertensive patients by administering a vasopeptidase inhibitor
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
MXPA04006917A (es) * 2002-01-17 2004-12-06 Novartis Ag Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra.
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US11622955B2 (en) * 2017-11-28 2023-04-11 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy

Also Published As

Publication number Publication date
CA2405496A1 (en) 2001-10-11
EP1267855A2 (en) 2003-01-02
JP2003533440A (ja) 2003-11-11
AU2001287289A1 (en) 2001-10-15
UY26648A1 (es) 2001-11-30
WO2001074348A8 (en) 2002-05-23
US20020004500A1 (en) 2002-01-10
WO2001074348A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
BRPI0412314B8 (pt) composto 3-[2(r)-{hidroxicarbonilpropil-amino}-2-feniletil]-5-(2-flúor-3-metoxifenil)-1-[2-flúor-6-(trifluorometil)benzil]-6-metil-pirimidina-2,4(1h,3h)-diona, composição farmacêutica compreendendo dito composto e uso do mesmo para o tratamento de uma condição relacionada ao hormônio sexual
PE20020082A1 (es) Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
PE20060999A1 (es) Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
PE20011316A1 (es) Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada
BRPI0412327A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
PE20071164A1 (es) Compuestos heterociclico fusionado como antagonista del receptor mineralocorticoide
PE20040439A1 (es) Combinacion de compuestos organicos
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
PE20070803A1 (es) Combinacion farmaceutica de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
UA84318C2 (ru) Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
WO2007061694A3 (en) Spirohydantoin tricyclic cgrp receptor antagonists
PE20060768A1 (es) Composicion farmaceutica que comprende hidroclorotiazida y telmisartano
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
PE20060477A1 (es) Compuestos piperazinodionas como antagonistas del receptor de oxitocina
PE20011114A1 (es) Decahidro-isoquinolinas
PE20011258A1 (es) Derivados de benzocicloalquilenilamina como antagonistas de receptores muscarinicos
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
HK1054692A1 (en) Composition containing an angiotensin ii receptor antagonist and a diuretic and its use for the treatment of hypertension

Legal Events

Date Code Title Description
FD Application declared void or lapsed